Asia Pacific Antibody Drug Conjugates Market Size & Outlook
Related Markets
Asia Pacific antibody drug conjugates market highlights
- The Asia Pacific antibody drug conjugates market generated a revenue of USD 1,049.6 million in 2021.
- The market is expected to grow at a CAGR of 18.7% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Other Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2022 to 2030.
Asia Pacific data book summary
| Market revenue in 2021 | USD 1,049.6 million |
| Market revenue in 2030 | USD 4,907.3 million |
| Growth rate | 18.7% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Other Cancer |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer, Other Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 18.1% of the global antibody drug conjugates market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 396.2 million by 2030.
Breast cancer was the largest segment with a revenue share of 49.45% in 2021. Horizon Databook has segmented the Asia Pacific antibody drug conjugates market based on blood cancer, breast cancer, other cancer covering the revenue growth of each sub-segment from 2018 to 2030.
The Asia Pacific ADC market is anticipated to witness significant growth over the forecast period due to the presence of emerging economies, increasing investments in biotechnology sector, improving government initiatives, and rapidly growing clinical research & outsourcing markets.
In addition, improvements in healthcare facilities and R&D in drug development are anticipated to propel market growth. The prevalence of cancer is expected to increase over the forecast period due to adoption of unhealthy lifestyle and increase in geriatric population.
The region has several biotech companies with multiple ADC products in their pipelines, along with manufacturing plants of companies that provide end-to-end manufacturing solutions for the same. Moreover, publicly funded payment options are provided in some of the more advanced economies of the region to combat the high occurrences of cancer therein.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific antibody drug conjugates market size, by country, 2018-2030 (US$M)
Asia Pacific Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
